Dequalinium induces human leukemia cell death by affecting the redox balance

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1395-1401

  García Pérez, Ana I ^a   Galeano, Eva ^b   Nieto, Elena ^a   Sancho, Pilar ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Antitumoral; Apoptosis; Dequalinium; DQAsomes; Glutathione; JNK; Leukemia; P38

Indexed keywords

DEQUALINIUM; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEQUALINIUM; DRUG SYNERGISM; GLUTATHIONE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MITOCHONDRIA; ORGAN SPECIFICITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; SUPEROXIDES; SURFACE-ACTIVE AGENTS;

EID: 80052090483     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.012     Document Type: Article

References (40)

1. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; May 14.
2. D'Souza G.G.M., Cheng S.M., Boddapati S.V., Horobin R.W., Weissig V. Nanocarrier-assisted subcellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel. J Drug Target 2008, 16(7):578-585.
3. Modica-Napolitano J.S., Aprille J.R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliver Rev 2001, 49:63-70.
4. Modica-Napolitano J.S., Nalbandian R., Kidd M.E., Nalbandian A., Nguyen C.C. The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with delocalized lipophilic cations. Cancer Lett 2003, 198:59-68.
5. Weissig V., Lizano C., Torchilin V. Micellar delivery system for dequalinium-a lipophilic cationic drug with anticarcinoma activity. J Liposome Res 1998, 8:391-400.
6. Helige C., Smolle J., Zellnig G., Fink-Puches R., Kerl H., Tritthart H.A. Effect of dequalinium on K1735-M2 melanoma cell growth, directional migration and invasion in vitro. Eur J Cancer 1992, 29A:124-128.
7. Abdul M., Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 2002, 186:99-105.
8. Christman J.E., Miller D.S., Coward P., Smith L.H., Teng N. Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies. Gynecol Oncol 1990, 39:72-79.
9. Aguilera D.G., Tsimberidou A.M. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009, 5(2):281-289.
10. Chen J., McMillan N.A. Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol Ther 2008, 7(2):174-179.
11. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984, 37:1035-1042.
12. Aichberger K.J., Mayerhofer M., Krauth M.T., Vales A., Kondo R., Derdak S., et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005, 65(20):9436-9444.
13. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773(8):1263-1284.
14. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108(7):2358-2365.
15. Champelovier P., El Atifi M., Pautre V., Rostaing B., Berger F., Seigneurin D. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors. Exp Hematol 2008, 36(1):28-36.
16. Matsukawa J., Matsuzawa A., Takeda K., Ichijo H. The ASK1-MAP kinase cascades in mammalian stress response. J Biochem 2004, 136(3):261-265.
17. Townsend D.M. S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv 2007, 7(6):313-324.
18. Moon D.O., Kim M.O., Choi Y.H., Kim N.D., Chang J.H., Kim G.Y. Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells. Cancer Lett 2008, 264(2):316-325.
19. Thornton T.M., Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 2009, 5(1):44-51.
20. Raman M., Chen W., Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 2007, 26(22):3100-3112.
21. Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S. MER1, a novel organic arsenic derivative, has potent PML-RARalpha- independent cytotoxic activity against leukemia cells. Invest New Drugs 2009; May 26.
22. Franco R., Cidlowski J.A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009, 16(10):1303-1314.
23. Galeano E., Nieto E., García-Pérez A.I., Delgado M.D., Pinilla M., Sancho P. Effects of the antitumoral Dequalinium on NB4 and K562 leukemia cell lines. Mitochondrial implication in cell death. Leuk Res 2005, 29(10):1201-1211.
24. Sancho P., Galeano E., Nieto E., Delgado M.D., García-Pérez A.I. Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res 2007, 31(7):969-978.
25. Curtin J.F., Donovan M., Cotter T.G. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 2002, 265:49-72.
26. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J.D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94(12):1765-1769.
27. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
28. Wang J., Li L., Cang H., Shi G., Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res 2008, 32(3):429-436.
29. Miyoshi T., Arai T., Yamashita K., Sasada M., Uchiyama T. NB4 cells treated with all-trans retinoic acid generate toxic reactive oxygen species that cause endothelial hyperpermeability. Leuk Res 2010, 34(3):373-378.
30. Han B., Ren Y., Guan L., Wei W., Hua F., Yang Y., et al. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells through mitochondria-dependent pathway. Oncol Res 2009, 17(8):373-381.
31. Sánchez Y., Amrán D., Fernández C., de Blas E., Aller P. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK AMPK). Int J Cancer 2008, 123(5):1205-1214.
32. Ramos A.M., Aller P. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Biochem Pharmacol 2008, 75(10):1912-1923.
33. Troyano A., Sancho P., Fernández C., de Blas E., Bernardi P., Aller P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Differ 2003, 10(8):889-898.
34. Liu L., Chen R., Huang S., Wu Y., Li G., Liu Q., et al. Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med Oncol 2010 Apr, 21. Epub ahead of print.
35. Pajuelo L., Calviño E., Diez J.C., Boyano-Adánez M.C., Gil J., Sancho P. Dequalinium induces apoptosis in peripheral blood mononuclear cells isolated from human chronic lymphocytic leukemia. Invest New Drugs 2010 Jun, 5.
36. Gao F., Yi J., Yuan J.Q., Shi G.Y., Tang X.M. The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 2004, 14(1):81-85.
37. Pérez C., Vilaboa N.E., García-Bermejo L., de Blas E., Creighton A.M., Aller P. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action. J Cell Sci 1997, 110:337-343.
38. Kasukabe T., Okabe-Kado J., Honma Y., Cotylenin A. a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci 2008, 99(8):1693-1698.
39. Viola G., Vedaldi D., Dall'Acqua F., Fortunato E., Basso G., Bianchi N., et al. Induction of gamma-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives. Biochem Pharmacol 2008, 75(4):810-825.
40. Chen X.Y., Yang H.X., Qu S.F., Liu J., Lv P., Xu J.P., et al. Involvement of p38 and c-Jun N-terminal protein kinase in cardiotoxin III-induced apoptosis of K562 cells. Biol Pharm Bull 2009, 32(4):583-588.